PMV Pharmaceuticals, Inc.
NASDAQ:PMVPBiotechnology
Healthcare
$1.31 +3.91%
+$0.04 today
- Market cap
- $69.86M
- Beta
- 1.36
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$1.47
52W Low $0.96High $1.88
Volume 1.19M
Average 0.38M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$73.58M
FY 2025 · Annual
Investing Cash Flow
$70.17M
FY 2025 · Annual
+31.5% YoYFinancing Cash Flow
$505,000.00
FY 2025 · Annual
+61.3% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (57.85M) | (73.32M) | (68.96M) | (58.71M) | (77.74M) |
| Depreciation & Amortization | 1.28M | 650K | 1.26M | 1.14M | 133K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.34M | 10.2M | 12.38M | 8.87M | 5.92M |
| Change in Working Capital | 4.12M | (568K) | 5.43M | (1.59M) | 914K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 191K | (389K) | 235K | 3.34M | (3.42M) |
| Other Working Capital | 3.93M | (179K) | 5.19M | (4.93M) | 4.34M |
| Other Non-Cash Items | 5.87M | 9.48M | (5.76M) | (997K) | (2.81M) |
| Operating Cash Flow | (46.57M) | (63.76M) | (55.66M) | (51.28M) | (73.58M) |
| Capital Expenditures | (1.35M) | (7.98M) | (962K) | (655K) | (29K) |
| Acquisitions (Net) | 0 | 0 | 0 | 251K | 31K |
| Purchases of Investments | (256.85M) | (229.2M) | (220.54M) | (148.29M) | (88.2M) |
| Sales of Investments | 114.61M | 235.82M | 170.96M | 202.04M | 158.37M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (143.58M) | (1.37M) | (50.55M) | 53.35M | 70.17M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 2.02M | 958K | 35.12M | 313K | 505K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 456K | 0 | 0 |
| Financing Cash Flow | 2.02M | 958K | 35.58M | 313K | 505K |
| Effect of Forex Changes | 1 | 0 | 34K | (35K) | 7K |
| Net Change in Cash | (188.13M) | (64.17M) | (70.59M) | 2.35M | (2.89M) |
| Free Cash Flow | (47.92M) | (71.74M) | (56.62M) | (51.94M) | (73.61M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$77.7M
+ D&A$133.0K
+ Stock-Based Comp$5.9M
+ Deferred Tax$0
+ Working Capital$914.0K
- Other Non-Cash-$2.8M
= Operating Cash Flow-$73.6M
- Capex-$29.0K
= Free Cash Flow-$73.6M
Analysis
FY2025 free cash flow is -$73.6M. FCF conversion is 94.7% of net income. Operating cash flow was -$73.6M, with capex of -$29.0K. The largest bridge item is Stock-Based Comp at $5.9M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 5, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 5, 2026 | |
| 8-K | Current report | Oct 5, 2026 |
Does PMVP generate free cash flow?
PMV Pharmaceuticals, Inc. (PMVP) generated -$73.61M of free cash flow in fiscal 2025.
How much operating cash flow does PMVP produce?
Operating cash flow was -$73.58M, before capital expenditures of $29,000.00.
Continue the stock analysis
Jump to another research area for this company.